[32]
In
Novopharm
, above, Justice Richard Mosley of the Federal Court considered the '080 patent in the context of an application for prohibition brought by Janssen in response to an NOA filed by Novopharm. Novopharm sought to market a generic levofloxacin drug product in Canada and alleged, in the NOA, that the '080 patent was invalid for lack of novelty, obviousness, ambiguity, overbreadth and lack of sufficiency.